10-K: MedWellAI Shifts Focus, Reports Continued Losses

MedWellAI, Inc. details its strategic pivot to health and wellness, reporting reduced commission revenues and significant net losses for the fiscal year ended June 30, 2026, while facing ongoing going concern risks.

Summary

• MedWellAI, Inc. has transitioned its business focus from digital asset mining to health and wellness, primarily earning commissions through an e-commerce platform connecting buyers with 503B pharmacies for GLP-1 therapies and other compounds.
• The company reported commission revenues of $437,857 for the year ended June 30, 2026, a decrease from $576,931 in the prior year, attributed to regulatory hurdles.
• Rental income contributed $90,000 in the fiscal year 2026.
• The company incurred a net loss of $1,589,465 for the year ended June 30, 2026, compared to a net loss of $3,607,145 for the year ended June 30, 2025.
• As of June 30, 2026, the company had total current assets of $111,877 and total current liabilities of $7,959,140, resulting in a significant working capital deficit.
• The auditor's report includes a going concern qualification due to recurring losses and negative cash flow from operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing net losses, significant accumulated deficit, and the auditor's going concern qualification, despite a strategic shift towards the health and wellness sector.

Positives

• Strategic shift towards the health and wellness sector, focusing on a commission-based e-commerce platform for pharmaceutical products.
• Generated $90,000 in rental income during the fiscal year 2026.
• Reduced general and administrative expenses by approximately 36% to $1,660,340 in fiscal year 2026 compared to $2,619,321 in fiscal year 2025, primarily due to lower stock-based compensation and consulting fees.
• The company has a new employment agreement with CEO Steve Rubakh, securing his leadership for an initial five-year term.

Negatives

• Commission revenues decreased by approximately 24% to $437,857 in fiscal year 2026 compared to $576,931 in fiscal year 2025, attributed to regulatory hurdles.
• Online sales revenue ceased entirely in fiscal year 2026, down from $17,837 in fiscal year 2025.
• Reported a net loss of $1,589,465 for the year ended June 30, 2026.
• Significant accumulated deficit of $90,263,345 as of June 30, 2026.
• Current liabilities ($7,959,140) significantly exceeded current assets ($111,877) as of June 30, 2026.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal controls over financial reporting were identified, including lack of independent directors and an audit committee financial expert.

Risks

• Changes in FDA regulation of compounded pharmaceuticals could adversely affect the supply of GLP-1 medications and other compounds.
• The company's use of artificial intelligence (AI) or other emerging technologies could adversely impact its business and financial results.
• Natural disasters and geo-political events could adversely affect the business.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights.
• The company is increasingly dependent on information technology systems and infrastructure, making it vulnerable to cybersecurity threats.
• Failure to attract, train, and retain technical and financial personnel could materially affect the business.
• The departure of CEO Steve Rubakh could significantly harm the business.
• The company's auditors report includes a going concern paragraph, raising doubts about its ability to continue operations.

Future Outlook

The company may need to raise additional capital for expansion or other operational expenses. Future funding requirements will depend on operational results and potential new development and administrative support expenses. The company anticipates seeking funding through public or private equity or debt financings, or other sources like collaboration agreements.

Management Comments

• Stock-based compensation expense decreased significantly in FY2026 compared to FY2025.
• The company is incurring increased costs due to being a publicly traded company, including legal, accounting, and compliance expenses.
• Management believes that the financial statements included in this report fairly present the company's financial condition, results of operations, and cash flows.

Industry Context

StockSavvy.ai notes that MedWellAI operates in the competitive compounded pharmaceutical space, focusing on weight management and peptide therapies. The company's reliance on FDA-registered 503B pharmacies and the evolving regulatory landscape for compounded drugs, particularly GLP-1 medications, are critical factors influencing its business model and future prospects.

Comparison to Industry Standards

• The company's revenue from commissions ($437,857 in FY2026) is modest compared to larger players in the pharmaceutical distribution or e-commerce sectors.
• The significant net loss and accumulated deficit highlight a common challenge for early-stage companies in highly regulated industries, where substantial investment is required before profitability is achieved.
• The company's reliance on a single officer and director, Steve Rubakh, for all key functions is a deviation from industry best practices, which typically emphasize diverse and independent leadership for robust corporate governance.

Corporate Governance

Legal Proceedings

• As of the date of filing, there were no pending or threatened lawsuits.

Related Party Transactions

• Steve Rubakh, the sole officer and director, received total compensation of $650,000 in FY2026 and FY2025.
• Accrued salary to Steve Rubakh totaled $711,115 as of June 30, 2026.

Stakeholder Impact

• Existing shareholders face potential dilution if additional capital is raised through equity offerings.
• Investors are cautioned about the company's going concern status and the risks associated with penny stock trading.
• The lack of independent directors and an audit committee may reduce protections for minority shareholders.

Next Steps

• Management plans to address the structure of the Board of Directors and discuss adding an audit committee during the fiscal year ending June 30, 2027.
• The company will continue to seek additional capital through various financing methods.
• The company will focus on its health and wellness e-commerce platform and rental income generation.

Key Dates

Recommendation

The company exhibits significant financial distress, including recurring net losses, a substantial accumulated deficit, and a going concern qualification from its auditors. While there is a strategic shift to a potentially growing market, the current financial instability and regulatory risks associated with compounded pharmaceuticals present a high level of risk for investors. The lack of independent corporate governance further exacerbates these concerns.

Keywords

MedWellAI, GLP-1, weight management, pharmaceuticals, e-commerce platform, 503B pharmacies, commission revenue, going concern